ClinicalTrials.gg
CompletedNCT05938647Updated Feb 9, 2026

Severe Dengue in Critical Care at Villavicencio, Colombia.

An observational study in Severe Dengue, sponsored by Hospital Departamental de Villavicencio. Completed at 2 sites in Colombia. Open to participants aged Up to 120 Years. Per ClinicalTrials.gov, last updated 2026-02-09.

Sponsored by Hospital Departamental de Villavicencio · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
199
Ages
Up to 120 Years
Sex
All
01

Study summary

Severe dengue is a cause of admission to critical care, especially in pediatric cases, and during epidemic outbreaks. Fluid support is basically the therapy offered, due to a scarcity of antiviral or immunological options to modulate the disease. Dengue is an endemic condition in tropical and subtropical regions as Villavicencio, and local ICUs provide care to the adult and pediatric population from the city and distant surrounding areas. National and international agencies' clinical guidelines have standard recommendations for the therapy of dengue shock syndrome (DSS), but data about performance is not available. Severity, organ dysfunction, hemorrhagic events, and capillary leak are predictors for decease. There are several epidemiological trials about dengue in the region, although publications about the characteristics of patients in ICU are nearly null. Currently, there is enough human resources and technology in ICU to provide an optimal care in cases of severe dengue. There is a need to recognize most appropriate strategies for the treatment of the disease, and their results, to adjust and provide better outcomes.

The aim of the study is to analyze the characteristics of patients with severe dengue admitted to the intensive care unit, to contribute to knowledge and better understanding of the disease in a specific clinical environment.

An observational retrospective study will be designed by the analysis of the ICU database of hospitals from Villavicencio, Colombia, since January to May 2023. The records of patients admitted with a diagnose of severe dengue will be exported to Excel for reviewing and debugging. Demographic information, laboratory results, severity scores, and outcomes will be examined. Categorical variables will be described by frequency and proportion; quantitative variables will be defined in a central and dispersion distribution. Chi-square and Mann-Whitney U test will be used to compare, according to the characteristics of the outcome.

It will be a pioneer study at this region, and it is necessary to determine the characteristics of patients admitted to the intensive care unit, the care provided, and the results of the treatment.

Read the detailed description

Dengue is an endemic viral infection in tropical and subtropical regions like Colombia, with epidemic outbreaks every three years, with severity especially in pediatric cases. Clinical symptoms, and signs are the fundamental strategies for the diagnosis, although they are not explicit for the disease, so it can be undetected. No specific antiviral therapy is available yet.

An increase in the vascular permeability is observed in severe cases. Some viral, and individual characteristics are recognized as risk factors for severity. Viral serotype, secondary infection, comorbidities, and individual genetic host factors predispose to a hyperinflammatory stage and increased response to the infection.

About 5% of severe cases have risk of mortality. Early detection of warning signs, hydration and appropriate care is crucial to prevent decease, and severe cases require proper attention in an ICU for monitoring, fluid restoration, and support of organ dysfunction.

Aggressive fluid therapy is proposed by national and international health organisms, based and limited trials. Crystalloids initial boluses and high fluid therapy are recommended to counter capillary leakage. It involves a risk of fluid overload with chances of secondary injury as pulmonary edema, tissue hypoperfusion, and organ disfunction.

Personalized monitoring of fluid therapy is necessary to achieve the goals of therapy, replacing fluid loss, but reducing timely the accumulated balance. ICU admission offers the opportunity to accomplish such a goal by adjusting the clinical practice guidelines to individual and dynamic needs, based in scientific evidence.

Several publications have evaluated strategies of fluid therapy in sepsis and shock, considering four overlapping phases (ROSE): resuscitation; optimization; stabilization; and evacuation. None of the studies have evaluated patients with dengue.

Determining the characteristics of patients admitted to the ICU by severe dengue, will provide essential information of severity, the therapy provided, the type of support delivered, and the outcomes attained. It will improve the knowledge about the accomplishment of clinical practice guidelines and its results.

02

Conditions studied

  • Severe Dengue

Browse trials for

03

In context

Severe Dengue

65 studies on the registry are indexed under Severe Dengue; 5 are open to participants now.

This study's enrollment of 199 is below the median of 667 across 13 observational studies indexed under Severe Dengue.

Browse Severe Dengue studies →

Lead sponsor

Hospital Departamental de Villavicencio is the lead sponsor of 16 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 120 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The participants in the trial are those patients treated in a critical care unit for dengue during the period of study, according to the registers of admission in the institution.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients admitted at a critical care unit with a diagnose of dengue either clinical or by a positive serology or molecular diagnostic methods.

Exclusion criteria

Exclusion Criteria:

  • Patients with a post admission diagnosis different than dengue either clinical or by a negative serology.
05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
199 participants (actual)
Patient registry
No

Groups and cohorts

  • Dengue hemorrhagic fever group 3

    Risk factor (severity 3): no diagnostic or therapeutic intervention; the characteristics of participants will be analyzed by demographics, severity, laboratory results, fluids accumulation, and outcomes.

    Other: Risk factor: group 3

  • DHF group 4 (DSS);

    Risk factor (group 4): no diagnostic or therapeutic intervention; the characteristics of participants will be analyzed by demographics, severity, laboratory results, fluids accumulation, and outcomes.

    Other: Risk factor: group 4

Interventions

  • OtherRisk factor: group 3

    Severe dengue, no shock. No diagnostic or therapeutic intervention; the characteristics of participants will be analyzed by demographics, severity, laboratory results, fluids accumulation, and outcomes.

  • OtherRisk factor: group 4

    Dengue shock syndrome. No diagnostic or therapeutic intervention; the characteristics of participants will be analyzed by demographics, severity, laboratory results, fluids accumulation, and outcomes

06

What researchers measure

Primary outcomes

  1. Number of deaths

    Hospital death

    Time frame: 30-days

Secondary outcomes

  1. Amount of fluid accumulation

    Daily positive fluid balance

    Time frame: 5 days

Other outcomes

  1. Number of ICU days

    Length of ICU stay

    Time frame: 30 days

  2. Number of hospital days

    Length of hospitalization

    Time frame: 30-days

  3. Number of participants with mechanical ventilation

    Need of mechanical ventilation

    Time frame: 30-days

  4. Number of days in mechanical ventilation

    Length of mechanical ventilation

    Time frame: 30-days

07

Study locations

2 sites
  • Clinica Primavera
    Villavicencio, Meta Department 50001, Colombia
  • Hospital Departamental de Villavicencio
    Villavicencio, Meta Department 50001, Colombia
08

References and documents

Publications

  • Chen CM, Chan KS, Yu WL, Cheng KC, Chao HC, Yeh CY, Lai CC. The outcomes of patients with severe dengue admitted to intensive care units. Medicine (Baltimore). 2016 Aug;95(31):e4376. doi: 10.1097/MD.0000000000004376. PubMed 27495047 ↗
  • Gupta S, Gupta M, Kashyap JR, Arora SK. Early cardiovascular involvement in dengue fever: A prospective study with two-dimensional speckle tracking echocardiography. Trop Doct. 2022 Apr;52(2):285-292. doi: 10.1177/00494755221076686. Epub 2022 Jan 31. PubMed 35098804 ↗
  • Madanayake P, Jayawardena A, Wijekoon SL, Perera N, Wanigasuriya J. Fluid requirement in adult dengue haemorrhagic fever patients during the critical phase of the illness: an observational study. BMC Infect Dis. 2021 Mar 20;21(1):286. doi: 10.1186/s12879-021-05971-6. PubMed 33743614 ↗
  • McBride A, Vuong NL, Van Hao N, Huy NQ, Chanh HQ, Chau NTX, Nguyet NM, Ming DK, Ngoc NT, Nhat PTH, Phong NT, Tai LTH, Tho PV, Trung DT, Tam DTH, Trieu HT, Geskus RB, Llewelyn MJ, Thwaites CL, Yacoub S. A modified Sequential Organ Failure Assessment score for dengue: development, evaluation and proposal for use in clinical trials. BMC Infect Dis. 2022 Sep 3;22(1):722. doi: 10.1186/s12879-022-07705-8. PubMed 36057771 ↗
  • Rosenberger KD, Alexander N, Martinez E, Lum LCS, Dempfle CE, Junghanss T, Wills B, Jaenisch T; DENCO Clinical Study Group. Severe dengue categories as research endpoints-Results from a prospective observational study in hospitalised dengue patients. PLoS Negl Trop Dis. 2020 Mar 4;14(3):e0008076. doi: 10.1371/journal.pntd.0008076. eCollection 2020 Mar. PubMed 32130212 ↗
  • Sachdev A, Pathak D, Gupta N, Simalti A, Gupta D, Gupta S, Chugh P. Early Predictors of Mortality in Children with Severe Dengue Fever: A Prospective Study. Pediatr Infect Dis J. 2021 Sep 1;40(9):797-801. doi: 10.1097/INF.0000000000003179. PubMed 34321449 ↗
  • Sengupta SP, Nugurwar A, Jaju R, Khandheria BK. Left ventricular myocardial performance in patients with dengue hemorrhagic fever and thrombocytopenia as assessed by two-dimensional speckle tracking echocardiography. Indian Heart J. 2013 May-Jun;65(3):276-82. doi: 10.1016/j.ihj.2013.04.017. Epub 2013 Apr 9. PubMed 23809381 ↗
  • Suwarto S, Nainggolan L, Sinto R, Effendi B, Ibrahim E, Suryamin M, Sasmono RT. Dengue score: a proposed diagnostic predictor for pleural effusion and/or ascites in adults with dengue infection. BMC Infect Dis. 2016 Jul 8;16:322. doi: 10.1186/s12879-016-1671-3. PubMed 27391122 ↗
  • Swamy AM, Mahesh PY, Rajashekar ST. Liver function in dengue and its correlation with disease severity: a retrospective cross-sectional observational study in a tertiary care center in Coastal India. Pan Afr Med J. 2021 Dec 23;40:261. doi: 10.11604/pamj.2021.40.261.29795. eCollection 2021. PubMed 35251455 ↗
  • Thanachartwet V, Desakorn V, Sahassananda D, Jittmittraphap A, Oer-Areemitr N, Osothsomboon S, Surabotsophon M, Wattanathum A. Serum Procalcitonin and Peripheral Venous Lactate for Predicting Dengue Shock and/or Organ Failure: A Prospective Observational Study. PLoS Negl Trop Dis. 2016 Aug 26;10(8):e0004961. doi: 10.1371/journal.pntd.0004961. eCollection 2016 Aug. PubMed 27564863 ↗
  • Trieu HT, Khanh LP, Ming DKY, Quang CH, Phan TQ, Van VCN, Deniz E, Mulligan J, Wills BA, Moulton S, Yacoub S. The compensatory reserve index predicts recurrent shock in patients with severe dengue. BMC Med. 2022 Apr 7;20(1):109. doi: 10.1186/s12916-022-02311-6. PubMed 35387649 ↗
  • Yacoub S, Trung TH, Lam PK, Thien VHN, Hai DHT, Phan TQ, Nguyet OPK, Quyen NTH, Simmons CP, Broyd C, Screaton GR, Wills B. Cardio-haemodynamic assessment and venous lactate in severe dengue: Relationship with recurrent shock and respiratory distress. PLoS Negl Trop Dis. 2017 Jul 10;11(7):e0005740. doi: 10.1371/journal.pntd.0005740. eCollection 2017 Jul. PubMed 28692675 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2024 to primary completion in Sep 2025, 14 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2023
First posted
Jul 10, 2023
StartActual
Jul 1, 2024
Primary completionActual
Sep 30, 2025
CompletionActual
Dec 20, 2025
Last update
Feb 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05938647
Lead sponsor
Hospital Departamental de Villavicencio
Collaborators
Cooperative University of Colombia
Responsible party
Norton Perez-Gutierrez, MD (Principal investigator, Hospital Departamental de Villavicencio) — Principal investigator
First posted
Jul 10, 2023
Start date
Jul 1, 2024
Primary completion
Sep 30, 2025
Completion
Dec 20, 2025
Last update
Feb 9, 2026

Study contacts

Norton Perez-Gutierrez, MD
principal investigator · Cooperative University of Colombia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion